Annexon Biosciences, Inc. (ANNX)
NASDAQ:ANNX
Want to see ANNX full AI Analyst Report?
ANNX Stock Chart & Stats
$6.54
-$0.26(-5.25%)
At close: 4:00 PM EST
$6.54
-$0.26(-5.25%)
Day’s Range― - ―
52-Week Range$1.85 - $7.18
Previous CloseN/A
Volume252.73K
Average Volume (3M)2.42M
Market Cap
$851.98M
Enterprise Value$498.43M
Total Cash (Recent Filing)$225.03M
Total Debt (Recent Filing)$25.43M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 17, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding163,842,540
10 Day Avg. Volume2,808,837
30 Day Avg. Volume2,424,198
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-177.13
Enterprise Value/Ebitda-2.49
Forecast
1Y Price Target
$14.00Price Target Upside114.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA sizable equity base combined with very low leverage provides durable financial flexibility for a clinical-stage biotech. This reduces immediate refinancing pressure, supports continued R&D spend, and gives management scope to execute clinical programs over the next several quarters without forced deleveraging.
Focused Therapeutic PlatformA clear, differentiated scientific focus on inhibiting C1q and the classical complement cascade creates a sustainable strategic advantage. A concentrated platform across neurodegenerative and autoimmune indications delivers program-level optionality and potential multi-indication applicability if clinical proof-of-concept is achieved.
Transparent Cash DynamicsFree cash flow tracking closely with net income indicates limited non-cash accounting distortions, making burn-rate forecasting more reliable. This transparency helps management and investors assess runway and plan financings or partnerships with clearer visibility into actual cash needs.
Bears Say
Pre-revenue LossesOperating without product revenue means ongoing R&D and operating costs are funded externally; large TTM net losses that widened versus prior year amplify funding dependency. Over a 2-6 month horizon this structural deficit raises execution risk if capital access tightens.
Accelerating Cash BurnSharp deterioration in free cash flow versus 2024 signals accelerating consumption of liquidity. Persistent high burn compresses runway, increasing the likelihood of near-term financings that can dilute shareholders and divert management attention from clinical execution.
Reliance On Public FinancingsA business model dependent on equity raises and occasional collaboration payments creates structural funding and dilution risk. With equity and assets trending down, continued reliance on public markets increases vulnerability to capital-market conditions and may constrain long-term program timelines.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences, Inc.’s price range in the past 12 months?
Annexon Biosciences, Inc. lowest stock price was $1.85 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences, Inc.’s market cap?
Annexon Biosciences, Inc.’s market cap is $851.98M.
When is Annexon Biosciences, Inc.’s upcoming earnings report date?
Annexon Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 67 days.
How were Annexon Biosciences, Inc.’s earnings last quarter?
Annexon Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.053.
Is Annexon Biosciences, Inc. overvalued?
According to Wall Street analysts Annexon Biosciences, Inc.’s price is currently Undervalued.
Does Annexon Biosciences, Inc. pay dividends?
Annexon Biosciences, Inc. does not currently pay dividends.
What is Annexon Biosciences, Inc.’s EPS estimate?
Annexon Biosciences, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Annexon Biosciences, Inc. have?
Annexon Biosciences, Inc. has 163,842,540 shares outstanding.
What happened to Annexon Biosciences, Inc.’s price movement after its last earnings report?
Annexon Biosciences, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 3.08%.
Which hedge fund is a major shareholder of Annexon Biosciences, Inc.?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (114.07% Upside)
$14.00 (114.07% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.78%
12-Months-Change
Fundamentals
Return on Equity
-101.19%
Trailing 12-Months
Asset Growth
-13.25%
Trailing 12-Months
Company Description
Annexon Biosciences, Inc.
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$14.00
▲(114.07% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.09% Insiders
17.76% Mutual Funds
42.32% Other Institutional Investors
19.61% Public Companies and
Individual Investors